GlassScriptPhysician profile
Michael Z Dibbs
NPI 1629073457
$7,267.20
in general payments reported to CMS, 2019-2025
36 companies · $960 in 2025
The $960 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $690 · 2021: $1,169 · 2022: $1,322 · 2023: $1,108 · 2024: $1,030 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,086.87 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $933.94 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.40 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $655.63 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $629.04 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $495.14 | 2019-2024 | |
| Pfizer INC. | $309.45 | 2019-2025 | |
| Amgen INC. | $305.68 | 2020-2025 | Repatha, Repatha |
| Aop Health US, LLC | $238.68 | 2025 | Rapiblyk |
| Esperion Therapeutics, INC. | $171.08 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $161.01 | 2021-2023 | |
| Amarin Pharma, INC. | $159.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.76 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $148.98 | 2021-2025 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $110.33 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $91.27 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $86.52 | 2021-2022 | |
| Scpharmaceuticals INC. | $81.75 | 2023-2025 | |
| Novo Nordisk INC | $81.28 | 2024-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $71.74 | 2025 | Shingrix, Arexvy |
| Actelion Pharmaceuticals US, INC. | $63.95 | 2019-2025 | Uptravi |
| Gilead Sciences, INC. | $61.89 | 2019 | |
| Boston Scientific Corporation | $60.57 | 2021-2025 | Watchman Flx, Patientcare Link |
| Philips North America LLC | $48.17 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $40.84 | 2023 | Inpefa |
| Abiomed | $38.06 | 2022 | |
| Xeris Pharmaceuticals, INC. | $36.86 | 2022 | |
| United Therapeutics Corporation | $31.40 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $23.48 | 2019-2020 | |
| Astellas Pharma US INC | $23.10 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.00 | 2019 | |
| Itamar Medical INC | $21.28 | 2023 | Watchpatone |
| Abbott Laboratories | $19.47 | 2021 | |
| Akcea Therapeutics, INC. | $18.16 | 2019 | |
| Chiesi USA, INC. | $13.00 | 2020 | |
| Bardy Diagnostics, INC. | $7.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.